Loading
Nektar Therapeutics Stock: price and insider trades · United States
Nektar Therapeutics: what insiders have been doing
Every trade that managers of Nektar Therapeutics disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in San Francisco, United States. It was founded in 1990. From 18 October 2025 to 18 October 2026, the disclosure feed for Nektar Therapeutics logged 21 filings by 11 insiders.
The flow runs one way only: 5 sales worth €193k, from 2 insiders, and no purchase. The largest single trade was a sale of €119k by Zalevsky Jonathan, published on 22 January 2026.
With 21 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Looking back to 2016, when coverage begins, insiders filed no purchases and 89 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 55.2 m USD and net income at -164.1 m USD.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
157
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€4M
89 ops. · all time
Who traded when
BuySaleHoward W. Robin10 sales
Jonathan Zalevsky10 sales
Mark Andrew Wilson5 sales
Analyst consensus: bullish or bearish?
Analysts rate Nektar Therapeutics Buy (bullish), based on 12 analysts. Average price target: US$133.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,614 of 24,148 companies
33.0
score / 100
Value12
Quality54
FCF yld-17%
Earn yld-13%
EV/EBITDA·
ROE-36%
Gross mgn100%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$35.78
Analyst consensus
12 analystsBuy
US$50.00Target US$133.08(+272%)US$192.00
Income statement
RevenueUS$55.2M
Gross profitUS$55.2M100% margin
EBITDA-US$128.3M-232% margin
Net income-US$164.1M-287.8% margin
Valuation
PER (forward)-3.5x
P/Book1.4x
Beta1.27
Balance sheet & cash
Market capUS$1.2B
Total debtUS$85.8M
Free Cash Flow-US$208.7M
Debt / Equity15%
Profitability & ownership
ROE-35.8%
ROA-12.5%
% insiders0.4%
% institutions107.1%
Last declaration on 25 September 2026
Declarations157 total
2,000 shares0Common StockSEC:0001193125-26-403101:0
2,000 shares0Common StockSEC:0001193125-26-403099:0
2,000 shares0Common StockSEC:0001193125-26-403097:0
2,000 shares0Common StockSEC:0001193125-26-403103:0
2,000 shares0Common StockSEC:0001193125-26-403105:0
418 shares@ US$71.980.0015% mcap1.3% of flowCommon StockSEC:0001193125-26-359586:0
186 shares@ US$71.980.0007% mcap0.9% of flowCommon StockSEC:0001193125-26-359588:0
418 shares@ US$71.97830.0015% mcap1.3% of flowCommonSEC144:0001959173-26-006164
186 shares@ US$71.97830.0007% mcap0.9% of flowCommonSEC144:0001959173-26-006172
5,681 shares@ US$65.390.019% mcap53.4% of flowCommonSEC144:0001950047-26-006656
10,000 shares@ US$60.270.025% mcap26.0% of flowCommonSEC144:0001959173-26-004730
10,000 shares@ US$60.960.025% mcap26.1% of flowCommonSEC144:0001959173-26-004688
5,538 shares@ US$59.380.014% mcap46.6% of flowCommonSEC144:0001950047-26-006135
180 shares@ US$73.000.8% of flowCommon StockSEC:0001193125-26-061886:0
423 shares@ US$73.001.3% of flowCommon StockSEC:0001193125-26-061885:0
3,867 shares@ US$35.678.8% of flowCommon StockSEC:0001193125-26-019843:0
6,250 shares0Common StockSEC:0001193125-25-331189:0
21,667 shares0Common StockSEC:0001193125-25-331187:0
7,110 shares0Common StockSEC:0001193125-25-297850:0
2,666 shares0Common StockSEC:0001193125-25-297855:0
1,903 shares0Common StockSEC:0001193125-25-297852:0
2,100 shares@ US$45.164.0% of flowCommon StockSEC:0000950170-25-114365:0
1,923 shares@ US$32.3741.7% of flowCommon StockSEC:0000950170-25-113691:0
793 shares@ US$32.4343.1% of flowCommon StockSEC:0000950170-25-113692:0
1,500 shares@ US$30.1630.3% of flowCommon StockSEC:0000950170-25-113129:0
25 of 157 declarations
About Nektar Therapeutics
Nektar Therapeutics is a United States-based biopharmaceutical company listed on the Nasdaq market, with corporate headquarters in San Francisco, California. For international investors, it should be viewed as a clinical-stage immunology company rather than a broad commercial pharma platform. Its valuation drivers are therefore centered on clinical data, regulatory milestones, financing capacity, and the strategic optionality of its pipeline.
The company was founded in the 1990s and built its scientific identity around polymer chemistry, drug design, and immune-system modulation. Over time, Nektar developed a reputation for translating proprietary science into partnerable assets, and its technology has contributed to several medicines commercialized globally through collaborations with large pharmaceutical companies. That legacy matters because it shows the company has historically been able to convert scientific innovation into real-world therapeutic products, even though its present investment case is now more focused on its wholly owned pipeline.
Read moreShow less
Today, Nektar’s core business is the discovery and development of novel immunology therapies intended to selectively induce, amplify, attenuate, or prevent immune responses. Its lead clinical asset is rezpegaldesleukin, an IL-2 pathway agonist and regulatory T-cell proliferator being studied in moderate-to-severe atopic dermatitis and severe-to-very severe alopecia areata. The company also continues to advance earlier-stage programs such as NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255, giving the portfolio exposure to autoimmune disease and oncology-related immunology. This focus creates scientific clarity, but it also concentrates execution risk in a relatively small number of programs.
In competitive terms, Nektar operates in a crowded and highly innovative segment of biotechnology, where differentiated mechanism of action and clean clinical data can quickly change investor sentiment. Its competitive positioning is based on the potential to deliver disease-modifying treatments with a targeted immunology approach. However, because it remains a clinical-stage company, it does not yet have the diversified revenue base of a mature pharmaceutical group, and it remains dependent on trial outcomes, capital markets access, and regulatory progress.
Recent developments have been materially important. In 2025 and 2026, Nektar reported positive phase 2b data for rezpegaldesleukin in atopic dermatitis, received FDA Fast Track designation for rezpegaldesleukin in atopic dermatitis and alopecia areata, completed or advanced target enrollment in key studies, and continued to present new data at major medical conferences. In its first-quarter 2026 reporting, the company also highlighted a follow-on equity financing and stated that it expects to initiate a phase 3 program in atopic dermatitis in June 2026. Overall, Nektar Therapeutics remains a Nasdaq-listed U.S. biotech story with meaningful upside linked to clinical execution, but with the usual high-risk profile of development-stage pharma.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
